BioNTech Collaborators

on April 15, 2023 IN CONflict$

While looking up something else on their website in relation to another po s t I’m doing, I took some notes from BioNTech’s About Us > Collaborators page.

Right Before Covid: (2018/2019)

“In July 2018, we formed a strategic partnership with Genevant (mRNA)“
“In August 16, 2018 – BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines.” ^⁽⁰¹⁾
“In October 2018, we entered into a research collaboration with the University of Pennsylvania” ^⁽⁰²⁾
“In September 2019, we entered into a partnership with the Bill & Melinda Gates Foundation“. ^{⁽⁰³⁾ ⁽⁰⁴⁾ ⁽⁰⁵⁾ ⁽⁰⁶⁾ ⁽⁰⁷⁾ ⁽⁰⁸⁾}

2020:

On Pfizer’s Site: On March 11, 2020 the World Health Organization declared COVID-19 a pandemic. Just six days later, on March 17, Pfizer signed a letter of intent with BioNTech to co-develop a potential COVID-19 vaccine^{⁽⁰⁹⁾ ⁽¹⁰⁾ ⁽¹¹⁾ ⁽¹²⁾}
“On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to develop and commercialize COVID-19 vaccines” ^⁽¹³⁾
“In July 2020, we began a strategic collaboration with Regeneron and Sanofi“^{⁽¹⁴⁾ ⁽¹⁵⁾ ⁽¹⁶⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾ ⁽²⁰⁾ ⁽²¹⁾ ⁽²²⁾ ⁽²³⁾}
“In November 2020, announced a multi-year strategic collaboration and joint AI Innovation Lab with InstaDeep to apply the latest advances in AI and ML technology”. ^{⁽²⁴⁾ ⁽²⁵⁾}

2021:

None mentioned on that url.

2022:

“In January 2022, we entered into a multi-target discovery collaboration with Crescendo Biologics (Humabody® VH platform)”. ^{⁽²⁶⁾ ⁽²⁷⁾ ⁽²⁸⁾}
“In February 2022, we entered into a 3-year, multi-target research collaboration with Medigene to develop T cell receptor (TCR)”. ^⁽²⁹⁾
“In November 2022, we entered into a multi-target research collaboration with Ryvu Therapeutics” ^⁽³⁰⁾

2023:

“In April 2023, we formed a global strategic partnership with Duality Biologics (tumors)“^{⁽³¹⁾ ⁽³²⁾}
“In March 2023, we entered into a license and collaboration agreement with OncoC4.” ^⁽³³⁾

Prior to 2018:

“In May 2015, we entered into a license and collaboration agreement with Genmab (DuoBody® / HexaBody® technology platforms).^{⁽³⁴⁾ ⁽³⁵⁾}
“In June 2015, we initiated a strategic partnership with Siemens to construct a fully automated, paperless and digitalized commercial cGMP-production site for individualized vaccines.”
“In November 2015, we announced a licensing, co-development and co-commercialization agreement with Sanofi (mRNA)”
“In September 2016, collaboration with Genentech/Roche group (mRNA).”

(https://www.biontech.com/int/en/home/about/collaborators.html)

Download PDF 📄

Unfortunately the PDF option doesn't print citations or any text that needs expanding. Will find another PDF solution another day - I've already lost half the day trying to get it to work. ~ May 9th, 2023

Telegram Channels: Get Post Updates | Post Comments | Videos

Get post updates from either Gettr or my Telegram channel: @JourneyToABetterLife. To comment on a post, the easiest way is to post in Telegram. (Note: I stopped logging into Facebook in January 2023 and haven't looked back!). Best way to reach me (although I don't login everyday) is putting a message in Telegram, Gettr, or SMS.

References[+]

References
01	August 16, 2018 – BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza – PDF – https://www.pfizer.com/print/pdf/node/555981 “Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines“
02	Oct 2018 – BioNTech and the University of Pennsylvania https://www.biontech.com/content/dam/corporate/pdf/20181104_20181105_BioNTech-and-the-University-of-Pennsylvania.pdf “provides us with the exclusivity to develop and commercialize mRNA immunotherapies for the treatment of up to 10 infectious disease indications with BNT163 entering the clinic in December 2022. https://investors.biontech.de/news-releases/news-release-details/biontech-starts-phase-1-clinical-trial-prophylactic-herpes/ BNT163 is an HSV vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1.”
03	BioNTech signed an agreement with the Bill & Melinda Gates Foundation in September, 2019, just before announcement in Wuhan China of the Novel Coronavirus and just before BioNTech made its stock market debut. The agreement involved cooperation on developing new mRNA techniques ‘to treat cancer and HIV’. – learn more on this post https://pennybutler.com/jp-gates/
04	...and if you’re new to the whole “coinciGates” – What else happened at this time? Hmm. in October 2019, the Event 201 Tabletop – funded by Gates – for a “global pandemic resulting from a new coronavirus” https://pennybutler.com/event201/
05	What else? oh, lots. See Tabletop Exercises post so I don’t have to try and summarize it here https://pennybutler.com/tabletop-exercises/
06	What else? On October 29, 2019 Dr Anthony Fauci (NIAID), Michael Specter (staff writer, global public health at The New Yorker since September 1998) , and Rick Bright (BARDA, now Rockefeller) conceptualized Live on C-Span having a “new outbreak of novel avian flu virus from China” so they can bypass the method of FDA approval and “enforce mRNA UNIVERSAL FLU vaccines“. https://pennybutler.com/2019-universal-flu-vaccine-cspan/
07	What else? On September 18, 2019, the WHO sent out a report to all it’s countries to coordinate a global preparedness to “Prepare the World for a Lethal Respiratory Pandemic and Universal Vaccine” that member countries were to implement “by September 2020” https://pennybutler.com/tabletop-world-at-risk/
08	How are these coinciGates, you ask? Gates was 2nd biggest funder of WHO at the time. Gates funded the Event 201 tabletop. Gates and Fauci have been collaborating since the 1990s with HIV/AIDS – Gates even purchased Fauci a house. There’s so much, best to read all posts tagged https://pennybutler.com/tag/bill-gates
09	Shot of a Lifetime: How Pfizer and BioNTech Developed and Manufactured a COVID-19 Vaccine in Record Time https://www.pfizer.com/news/articles/shot_of_a_lifetime_how_pfizer_and_biontech_developed_and_manufactured_a_covid_19_vaccine_in_record_time “March 17 2020, Pfizer signed a letter of intent with BioNTech to co-develop a potential COVID-19 vaccine”
10	Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-to-Co-Develop-Potential-COVID-19-Vaccine/default.aspx.
11	Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global Covid-19 Vaccine Development. Available at https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration
12	Interesting if you didn’t know – Pfizer’s CEO Albert Bourla cashed out 60% of his stock on the same day the company unveiled the results of its COVID-19 vaccine trial https://markets.businessinsider.com/news/stocks/pfizer-ceo-sold-stock-day-covid-19-vaccine-results-unveiled-2020-11-1029790705
13	Mar 16, 2020 – BioNTech teams up with Fosun Pharma to test Covid-19 mRNA vaccine in China — and scores $50M investment https://endpts.com/biontech-teams-up-with-fosun-pharma-to-test-covid-19-mrna-vaccine-in-china-and-scores-50m-investment/ “Fosun Pharma will team up with BioNTech to conduct trials of its Covid-19 vaccine, BNT162, in China. To get on board, Fosun bought $50 million worth of BioNTech equity $BNTX and promised up to $85 million more in payments.”
14	For any fellow nerd that actually bothers to read my references – Regeneron is one of the world’s largest and most sophisticated human genetics sequencing centers. Regeneron is one of the six drug companies (including AstraZeneca) that paid to sequence all the genes from 500,000 participants in the U.K. Biobank. Regeneron also partnered with Pennsylvania’s Geisinger Health System to sequence 250,000 of its patients. Regeneron is the actual company that did all the sequencing. More on this post: https://pennybutler.com/dna-harvesting-pcr/
15	REGEN-COV® (casirivimab and imdevimab) https://www.regeneron.com/home/covid19 “Regeneron Pharmaceuticals develops and manufactures Regeneron Monoclonal Antibodies.” “Monoclonal antibodies, such as REGEN-COV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation.” “REGEN-COV is not authorized for pre-exposure prophylaxis for prevention of COVID-19.”
16	chatGPT [an Unreliable Lying AI programme] also stated: “Regeneron collaborated with Sanofi to develop REGN-COV2. The partnership between Regeneron and Sanofi was announced in April 2020. Additionally, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported the clinical development of REGN-COV2. Roche and its subsidiary, Genentech, have partnered with Regeneron to develop, manufacture and distribute the treatment outside of the United States. GSK has also joined the partnership with Regeneron to develop, manufacture and distribute the treatment.” [I don’t trust a damn thing that comes out of chatGPT without double-checking references, take this with a grain of salt as I haven’t checked all of the statements that it’s not just telling porkies, but worthwhile looking up if you have the time – and if so, please share with me so that I don’t have to look up everything on my own :) (I will link the ones I verified below) ]
17	Regeneron is collaborating with Roche to increase global supply of REGEN-COV. Regeneron is responsible for development of the therapy in the U.S., and Roche is primarily responsible for development and distribution outside the U.S. https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-roche-collaborate-significantly-increase-global
18	Regeneron Pharmaceuticals – Wikipedia – https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals “In October 2017, Regeneron made a deal with the Biomedical Advanced Research and Development Authority (BARDA) that the U.S. government would fund 80% of the costs for Regeneron to develop and manufacture antibody based medications, which subsequently, in 2020, included their COVID-19 treatments”
19	Regeneron Pharmaceuticals – Wikipedia – https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals “In May 2020, Regeneron announced it would repurchase approx. 19.2 million of its shares for around $5 billion, held directly by Sanofi. Prior to the transaction, Sanofi held 23.2 million Regeneron shares”
20	Regeneron Pharmaceuticals – Wikipedia – https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals “On February 4, 2020, the U.S. Department of Health and Human Services (HHS), which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19″
21	Regeneron Pharmaceuticals – Wikipedia – https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals “In July 2020, under Operation Warp Speed, Regeneron was awarded a $450 million government contract to manufacture and supply its experimental treatment REGN-COV2, an artificial “antibody cocktail” which was then undergoing clinical trials for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 coronavirus infection. The $450 million came from the Biomedical Advanced Research and Development Authority (BARDA), the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and Army Contracting Command. “By funding this manufacturing effort, the federal government will own the doses expected to result from the demonstration project” “The FDA granted approval for emergency use authorization in November 2020”
22	Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-27-10-58-00-2022288 “Paris and Tarrytown, N.Y. – April 27, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with “severe” or “critical” respiratory illness caused by COVID-19.”
23	Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19 – Aug 18, 2020 https://www.gene.com/media/press-releases/14874/2020-08-18/genentech-and-regeneron-collaborate-to-s “The companies will collaborate on developing and manufacturing REGN-COV2. Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.”
24	InstaDeep > About https://www.instadeep.com/about-us/ “Our mission is to accelerate the transition to an AI-First World that benefits everyone.” “2018 – Partnered With Intel’s AI Builders Program” “2018 – Joined NVIDIA’s Inception Program” “2020 – First AI Collaboration With DeepMind” “2020 – BioNTech And InstaDeep Announce Strategic Collaboration And Form AI Innovation Lab To Develop Novel Immunotherapies”
25	InstaDeep > Research https://www.instadeep.com/research/papers/ — Remind me to go through every single one of these, look at the topics!!
26	Humabody® Technology Applications > Humabody Drug Conjugates https://www.crescendobiologics.com/partnering-overview/humabody-technology-applications/ “Humabody VH are ideal for delivering potent, toxic payloads for treatment of solid tumours whilst maximising the therapeutic index. Crescendo has extensive in-house experience of optimally configuring Humabody molecules for delivery of toxic payloads.”
27	Humabody® V_H Platform https://www.crescendobiologics.com/humabody-vh-platform/ “Humabody VHs are the smallest part of an antibody capable of specific antigen binding, about a tenth the size of a standard antibody.” “Crescendo’s Humabody V_Hs offer a range of delivery routes for administration such as IV, subcutaneous, topical, pulmonary, oral, and ocular. Crescendo is able to mine a broad spectrum of fully human VHs with different binding characteristics and broad epitope coverage against virtually any target. VH raised against different targets can be formatted with flexible linkers to generate multispecifc, multifunctional therapeutic molecules (Multibody® VH) with novel mechanisms of action that cannot be achieved with standard antibodies. Crescendo’s technology also enables modulation of half-life extension.”
28	Humabody® Technology Applications > Oncolytic Viruses https://www.crescendobiologics.com/partnering-overview/humabody-technology-applications/ “Humabody V_H can be encoded as formatted ‘payloads’ within an oncolytic virus, delivering therapeutically active molecules directly into the tumour microenvironment. Virus induced immunogenic cancer cell death combined with T cell engagement by Humabody V_Hs has the potential to unlock immune suppression in the tumour, turning immunologically ‘cold’ tumours ‘hot’.”
29	Medigene https://medigene.com/ “Publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.”
30	Ryvu Therapeutics https://ryvu.com/about-us/ “clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology.”
31	Duality Biologics https://www.dualitybiologics.com/about.html?md=1 “DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases.” “The company was founded in January 2020 by Dr. John Zhu” “We are currently operating in both China and United States.” “…we have successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. These include DITAC (Duality Immune Toxin Antibody Conjugate) with significantly improved therapeutic window and DIMAC (Duality Immune Modulating Antibody Conjugate) with superior efficacy than traditional biologics.” “Additionally, we are continuing evolving our protein engineering and ADC technology for the next wave of “super ADC” molecules including diverse payload class, bispecific ADC and dual payload ADC to further harness the potential of ADC modality.”
32	BioNTech and Duality Biologics Team Up to Develop ADC Drug Candidates https://www.chemdiv.com/company/media/pharma-news/2023/biontech-and-duality-biologics-team-up-to-develop-adc-drug-candidates/ “BioNTech and China-based Duality Biologics have inked a licensing and collaboration deal to develop two antibody-drug conjugates (ADCs).” “ADCs combine antibodies and their targeting abilities with either chemotherapy or other anticancer agents.” “Under the terms of the partnership, BioNTech will gain access to Duality Biologics’ lead candidate DB-1303, a topoisomerase-1 inhibitor-based ADC aimed towards human epidermal growth factor receptor 2 (HER2), which is expressed in several cancers, including breast, bladder, pancreatic, ovarian and stomach cancers.” “DB-1303 has shown potent antitumor activity in both HER2-positive and HER2-low tumor models.” “The FDA has granted Fast Track Designation to DB-1303 and the drug candidate is being evaluated in a phase 2 clinical trial in HER2-expressing advanced solid tumors.” “Duality Biologics will receive upfront payments totaling $170 million and is eligible for potential milestone payments of more than $1.5 billion.”
33	Biontech and Oncoc4 Announce Strategic Collaboration to Co-develop And Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications https://oncoc4.com/index.php/blog/news-releases/item/14-biontech-and-oncoc4-announce-strategic-collaboration-to-co-develop-and-commercialize-novel-checkpoint-antibody-in-multiple-solid-tumor-indications “BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel biologicals for cancer treatment, today announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances.”
34	Genmab https://www.genmab.com/research-innovation/antibody-technology-platforms/ “Using our proprietary DuoBody®, HexaBody®, DuoHexaBody® and HexElect® technologies, we can harness the power of human antibodies to develop a robust pipeline of products that builds on natural antibody biology with the aim of transforming how cancer and other serious diseases are treated.”
35	Genmab Major Shareholders https://ir.genmab.com/stock-information/major-shareholders#content “BlackRock & Wellington Management Group LLP”

Penny... on Health

Truth-seeker, ever-questioning, ever-learning, ever-researching, ever delving further and deeper, ever trying to 'figure it out'. This site is a legacy of sorts, a place to collect thoughts, notes, book summaries, & random points of interests.

DISCLAIMER: The information on this website is not medical science or medical advice. I do not have any medical training aside from my own research and interest in this area. The information I publish is not intended to diagnose, treat, cure or prevent any disease, disorder, pain, injury, deformity, or physical or mental condition. I just report my own results, understanding & research.

View my other posts

BioNTech Collaborators

Related posts